Mumbai, Dec 21: Suven Life Sciences a biopharmaceutical company said that it has secured one product patent from Canada and
one product patent from India corresponding to the New Chemical
Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid
through 2034
and 2028 respectively.
The granted claims of the patents include the class of selective 5-HT4 and 5-HT6 compounds respectively and are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia respectively, company ssid in afiling with BSE. UNI
The granted claims of the patents include the class of selective 5-HT4 and 5-HT6 compounds respectively and are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia respectively, company ssid in afiling with BSE. UNI
Post A Comment:
0 comments so far,add yours